metformin has been researched along with Acute Onset Vascular Dementia in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tzeng, IS | 1 |
| Hsieh, TH | 1 |
| He, Y | 1 |
| Li, Z | 1 |
| Shi, X | 1 |
| Ding, J | 1 |
| Wang, X | 1 |
2 other studies available for metformin and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan.
Topics: Aged; Dementia, Vascular; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hospitals; | 2023 |
Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion.
Topics: Animals; Brain Ischemia; Carotid Stenosis; Cognitive Dysfunction; Dementia, Vascular; Diabetes Melli | 2023 |